FTC Report on Pharmacy Benefit Managers May Boost NJ’s Insulin MDL
By Lisa Willis
Jan 21, 2025
The FTC’s new report on pharmacy benefit managers strengthens New Jersey’s insulin MDL, say Tal Lifshitz and Ben Wotlanzki. They argue the findings—revealing $7.3 billion in inflated drug revenues and broken rebate systems—reinforce arguments that PBMs manipulated insulin pricing. Their analysis predicts expanded litigation and heightened scrutiny of PBM practices in the MDL.
Click here to read the original article.
